PMID- 14613436
OWN - NLM
STAT- MEDLINE
DCOM- 20031204
LR  - 20230823
IS  - 1083-4087 (Print)
IS  - 1944-706X (Electronic)
IS  - 1083-4087 (Linking)
VI  - 9
IP  - 5 Suppl
DP  - 2003 Sep-Oct
TI  - Emerging therapeutic strategies for asthma management.
PG  - 14-21
LID - 10.18553/jmcp.2003.9.s5.14
AB  - OBJECTIVE: The describe the mechanisms of action of and clinical experience to 
      date with novel asthma drug therapies. DATA SOURCES: This article is based, in 
      part, on a presentation given by Eli O. Meltzer, MD, at a symposium entitled. New 
      Frontiers in Asthma Management: Biotechnology for Optimal Therapeutic and 
      Economic Outcomes. at the Academy of Managed Care Pharmacy's 15th Annual Meeting 
      and Showcase in Minneapolis, Minnesota, on April 10, 2003. CONCLUSIONS: Various 
      elements of the pathophysiologic processes involved in allergic asthma, including 
      type 2 helper T lymphocytes, cytokines, and immunoglobulin E (IgE), have been the 
      targets of new drug research. Clinical experience with omalizumab, a humanized 
      anti-IgE monoclonal antibody, is promising.
FAU - Sullivan, Sean D
AU  - Sullivan SD
AD  - Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, 
      University of Washington, 1959 NE Pacific Ave., Box 357630, Seattle, WA 98195, 
      USA. sdsull@u.washington.edu
FAU - Meltzer, Eli O
AU  - Meltzer EO
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - J Manag Care Pharm
JT  - Journal of managed care pharmacy : JMCP
JID - 9605854
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Anti-Asthmatic Agents)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Antibodies, Anti-Idiotypic)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Cytokines)
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (Phosphodiesterase Inhibitors)
RN  - 2P471X1Z11 (Omalizumab)
SB  - IM
MH  - Adjuvants, Immunologic/therapeutic use
MH  - Anti-Asthmatic Agents/therapeutic use
MH  - Anti-Inflammatory Agents/therapeutic use
MH  - Antibodies, Anti-Idiotypic
MH  - Antibodies, Monoclonal/therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Asthma/drug therapy/immunology/*therapy
MH  - Clinical Trials as Topic
MH  - Cytokines/metabolism
MH  - Humans
MH  - Immunosuppressive Agents/therapeutic use
MH  - Omalizumab
MH  - Phosphodiesterase Inhibitors/therapeutic use
MH  - Practice Guidelines as Topic
MH  - Risk Factors
PMC - PMC10437301
EDAT- 2003/11/14 05:00
MHDA- 2003/12/05 05:00
PMCR- 2003/09/01
CRDT- 2003/11/14 05:00
PHST- 2003/11/14 05:00 [pubmed]
PHST- 2003/12/05 05:00 [medline]
PHST- 2003/11/14 05:00 [entrez]
PHST- 2003/09/01 00:00 [pmc-release]
AID - 2003(9)5: 14-21 [pii]
AID - 10.18553/jmcp.2003.9.s5.14 [doi]
PST - ppublish
SO  - J Manag Care Pharm. 2003 Sep-Oct;9(5 Suppl):14-21. doi: 
      10.18553/jmcp.2003.9.s5.14.